<DOC>
	<DOCNO>NCT00797823</DOCNO>
	<brief_summary>This study aim test insulin glucagon delivery algorithm design use conjunction continuous glucose monitoring system . This combine glucose sensing/hormone delivery approach step way eventual development artificial ( automate ) pancreas . The insulin glucagon delivery algorithm base difference current blood glucose target glucose ( proportional error ) rate change blood glucose ( derivative error ) , adjust recent glucose history . This algorithm call Fading Memory Proportional-Derivative ( FMPD ) Algorithm . The principal investigator study publish previous research regard use algorithm find well-suited control blood glucose type 1 diabetic animal . The addition glucagon helpful ; good glycemic control few glucose excursion observe small intermittent infusion subcutaneous glucagon give time impend low blood sugar ( Ward et al . 2008 ) .</brief_summary>
	<brief_title>Sensor-Augmented Insulin Delivery : Insulin Plus Glucagon Versus Insulin Alone</brief_title>
	<detailed_description>The objective current human study compare glycemic control person Type 1 Diabetes use FMPD Insulin plus Glucagon Delivery Algorithm vs. FMPD Insulin-Alone Algorithm . Subjects undergo two 28-hour sensor-augmented glycemic control study . Each subject fit two short term continuous glucose monitor system two subcutaneous ( SC ) infusion catheter . These catheter allow SC delivery insulin glucagon ( insulin plus glucagon placebo ) . The accuracy wire sensor verify every 10 minute venous blood glucose test . For first 4 hour , insulin glucagon delivery control venous blood order ass compare accuracy two sensor , accurate sensor ( remain accurate ) control FMPD algorithm . The main outcome study time spend target range ( 70 - 180 mg/dl ) percentage study require intervention due hypoglycemia ( glucose &lt; 70 mg/dl ) . The accuracy sensor life study also evaluate . The specific system use study frequent blood test use two separate infusion pump feasible every day use individual diabetes . However , glucose control algorithm ( without use glucagon ) provide effective blood glucose management long time period calculation program may integrate continuous blood glucose monitoring system insulin glucagon pump .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Age 2165 , history Type 1 Diabetes Mellitus &gt; 3 month . Women : For woman childbearing potential , negative urine pregnancy test require first day study prior sensor insertion AND subject must agree use contraception prior study . For menopausal woman undergone surgical sterilization , pregnancy test contraception require . Willingness attend clinic visit participate two 28hour study one 9hour study . Hemoglobin A1C 5.010 % . ( Values 5.0 suggest severe tendency towards hypoglycemia , value 10 % suggest severely uncontrolled diabetes risk ketoacidosis . ) Body mass index 1935 . Pregnancy , lactation refusal use contraception . Use investigational drug 30 day prior screen . Enrollment participation research study 30 day prior entirety sensor insertion . Current alcohol abuse , substance abuse , severe mental illness ( judge Principal Investigator ( PI ) ) . Any prior cerebrovascular accident major permanent neurological damage aphasia , hemiparesis , dementia . A history cerebrovascular disease cardiovascular disease regardless time since occurrence . Coronary artery disease ( symptomatic asymptomatic ) manifest unstable angina , acute coronary syndrome , myocardial infarction therapeutic coronary procedure ( e.g. , Percutaneous Transluminal Coronary Angioplasty ( PTCA ) , stent placement , Coronary Artery Bypass Grafting ( CABG ) ) within prior 6 month . Any degree heart failure ( defined New York Heart Association ) .. Renal insufficiency ( serum creatinine &gt; 2.5 ) . Current foot leg ulceration . Peripheral arterial disease uncontrolled claudication . Active uncontrolled malignancy except basal cell squamous cell skin cancer . Concurrent illness , diabetic mellitus , control stable therapeutic regimen . Hemoglobin A1C le 5.0 great 10 % . A total bilirubin level 1.5 mg/dl . Medications : Oral parenteral corticosteroid ( glucocorticoid therapy ) exclusion ; topical corticosteroid . Any chronic immunosuppressive medication ( cyclosporine , azathioprine , sirolimus , tacrolimus ) . Visual impairment would prevent read display Medtronic Guardian® Receiver . Physical impairment would prevent use button Medtronic Guardian® Receiver . Serum Alanine Transaminase ( ALT ) Aspartate Transaminase ( AST ) ≥3x upper limit normal . Serum albumin level &lt; 3.2 g/dl . Severe anemia define hematocrit &lt; 28 % . Severe serum electrolyte abnormality ( sodium , potassium , carbon dioxide , chloride ) . Cardiac rhythm disturbance characterize : 2nd 3rd degree heart block , bradycardia le 50 bpm ( exception bradycardia aerobic athlete ) , tachycardia great 100 bpm , arrhythmia judge investigator exclusionary . A history Human Immunodeficiency Virus ( HIV ) infection . An active hepatitis infection . Known allergy type insulin Insulin resistance require 200 unit insulin per day Known bleeding disorder chronic usage warfarin . Any known seizure disorder . Past history pheochromocytoma family history Multiple Endocrine Neoplasia ( MEN ) 2A , MEN 2B , neurofibromatosis , von HippelLindau disease . Hypoglycemic unawareness chronic hypoglycemia . A severe hypoglycemic event require hospitalization within past two year . Adrenal insufficiency . Insulinoma . Use acetaminophen ascorbic acid . Impaired mentation psychiatric diagnosis Uncontrolled candidiasis . Any known allergy glucagon .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>diabetes</keyword>
	<keyword>pancreas</keyword>
	<keyword>beta cell</keyword>
	<keyword>glucagon</keyword>
	<keyword>insulin</keyword>
	<keyword>hypoglycemia</keyword>
</DOC>